title: Development of alopecia areata universalis in a patient receiving adalimumab.
authors.forename: Natalie
authors.initials: N
authors.lastname: Garcia Bartels
authors.forename: Hae-Huyk
authors.initials: HH
authors.lastname: Lee
authors.forename: Margitta
authors.initials: M
authors.lastname: Worm
authors.forename: Gerd-Rüdiger
authors.initials: GR
authors.lastname: Burmester
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
authors.forename: Ulrike
authors.initials: U
authors.lastname: Blume-Peytavi
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab